Neurosessments: Developing a quick, objective motor test to prompt cognitivetesting in primary care

神经评估：开发快速、客观的运动测试以促进初级保健中的认知测试

• 批准号: 10759203
• 负责人: Jill Winquist Love
• 金额: $ 34.56万
• 依托单位: NEUROSESSMENTS LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2024-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10759203
• 关键词: Adopted; Adult; Affect; Age; Agreement; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease brain; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; American; Amyloid; Arizona; Behavioral; Black American; Black race; Brain; Brain Pathology; Caring; Cause of Death; Clinic; Clinical; Clinical assessments; Cognitive; Collection; Community Health; Copyright; Data; Decision Making; Dementia; Detection; Diagnosis; Diagnostic Reagent Kits; Diagnostic tests; Disease; Elderly; Evaluation; Family; Gifts; Goals; Individual; Intellectual Property; Judgment; Kidney Bean; Knowledge; Legal; Legal patent; Life; Link; Medical; Medical Staff; Memory; Motor; Movement; Neuropsychology; Nursing Students; Online Systems; Paper; Patient Education; Patient Self-Report; Patients; Phase; Physicians; Primary Care; Primary Care Physician; Probability; Process; Provider; Publishing; Racial Equity; Recommendation; Research; Research Assistant; Research Training; Rights; Sampling; Screening procedure; Self Care; Site; Small Business Innovation Research Grant; Specialist; Students; System; Technology; Testing; Time; United States; Universities; Upper Extremity; Visit; care providers; caucasian American; cerebral atrophy; clinical practice; cognitive testing; commercial application; commercialization; digital; early screening; empowerment; follow-up; functional decline; human old age (65+); improved; innovation; motor behavior; motor deficit; nursing administration; power analysis; pre-clinical; primary care provider; primary care setting; routine screening; screening; sex; technological innovation; tool development; usability

PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is the leading cause of dementia in the United States, affecting one out of every nine older adults. However, Alzheimer’s disease and related dementias (AD/ADRD) can be difficult to diagnose, with physicians missing nearly half of all probable dementia cases. Rates of missed diagnosis are even higher among Black older adults. The majority of physicians do not regularly screen their patients with cognitive tests, due mostly to a lack of time during their face-to-face time with patients. Thus, there is a clear need for a quick, objective test that can be administered by medical staff prior to the physician’s time with the patient, which will prompt cognitive testing or a specialist referral for follow-up when there is concern for AD/ADRD. Since research has shown that motor regions in the brain are affected early in the progression of AD, the long-term goal of Neurosessments LLC is to develop a motor test that will help improve dementia detection in primary care that is appropriate for older adults from diverse backgrounds. Prior research by the Neurosessments LLC team has developed an experimental version of a motor test that can identify dementia, predict functional decline, and detect brain amyloid, regardless of the patient’s educational attainment, sex, or age. The overall objective of this Phase I SBIR is to adapt the original version of this motor test into a quick (<2 minutes) and easy to administer version called qBEANS (quick Behavioral Exam to Advance Neuropsychological Screening) for medical staff to use. The specific aims are to 1) determine the reliability and racial equity of a short version of the motor test and 2) develop a digital user interface for administering and scoring the motor test that is usable in a clinical setting. Achieving these aims will lead to a Phase II SBIR that deploys qBEANS within primary care offices and community health clinics to increase rates of cognitive testing and improve dementia detection. This proposal is innovative in its use of motor behavior to detect probable dementia in its early stages, and its development of tools for intended use in primary care. The commercialization plan is to sell single-use test kits to medical providers for use in primary care settings to annually screen adults ages 65 and older. Through routine screening, primary care providers will be able to identify individuals whose scores indicate possible dementia, informing providers of whether or not to perform additional cognitive testing or refer to specialists for possible diagnosis of AD/ADRD. The societal impact is that it will improve the rates of early dementia diagnosis, giving older adults and their families the gift of time to make decisions about treatment options, legal plans, personal care plans, and finances.

项目概要/摘要 阿尔茨海默病 (AD) 是美国痴呆症的主要原因，影响了九分之一的人 然而，阿尔茨海默病和相关痴呆症 (AD/ADRD) 可能很难诊断。 医生漏诊了近一半可能的痴呆症病例，漏诊率甚至更高。 大多数黑人老年人不会定期对患者进行认知测试，因为 主要是因为他们缺乏与患者面对面的时间，因此，显然需要快速、有效的方法。 客观测试可以由医务人员在医生与患者接触之前进行，这将 当担心 AD/ADRD 时，立即进行认知测试或转诊专家进行随访。 研究表明，大脑的运动区域在 AD 进展的早期就受到影响，AD 的长期目标是 Neurosessments LLC 将开发一种运动测试，有助于改善初级保健中的痴呆症检测 Neurosessments LLC 团队之前的研究表明，适合来自不同背景的老年人。 开发了运动测试的实验版本，可以识别痴呆症，预测功能衰退，并 检测大脑淀粉样蛋白，无论患者的教育程度、性别或年龄如何。 第一阶段 SBIR 旨在将该运动测试的原始版本改编为快速（<2 分钟）且易于管理的测试 名为 qBEANS（快速行为检查以推进神经心理筛查）的版本，供医务人员 具体目的是 1) 确定简短版本的运动测试的可靠性和种族公平性。 2) 开发一个数字用户界面，用于管理和评分可在临床环境中使用的运动测试。 实现这些目标将导致第二阶段 SBIR 在初级保健办公室和 社区卫生诊所提高认知测试率并改善痴呆症检测。 其创新之处在于利用运动行为来检测早期可能的痴呆症，以及它的开发 商业化计划是将一次性测试套件出售给医疗机构。 供初级保健机构每年对 65 岁及以上的成年人进行常规筛查， 初级保健提供者将能够识别其分数表明可能患有痴呆症的个人，并告知 提供者是否进行额外的认知测试或转介专家进行可能的诊断 AD/ADRD 的社会影响是它将提高痴呆症的早期诊断率，为老年人提供帮助。 及其家人有时间就治疗方案、法律计划、个人护理计划做出决定， 和财务。